EAM
KRYS icon

Eagle Asset Management’s Krystal Biotech KRYS Stock Holding History

Eagle Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$12.7M Sell
63,602
-12,657
-17% -$2.44M 0.06% 250
2024
Q2 		$13.9M Buy
+76,259
New +$12.8M 0.07% 228

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's KRYS Position: Q3 2024 in Review

Eagle Asset Management reduced its Krystal Biotech (KRYS) stake by 17% in Q3 2024, selling an estimated $2.44M and leaving 63,602 shares worth $12.7M. The position accounts for 0.06% of the portfolio, ranked #250.

Eagle Asset Management first reported a position in KRYS in Q2 2024 and has held it in 2 quarters since. The position peaked at $13.9M in Q2 2024. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Eagle Asset Management held 63,602 shares of Krystal Biotech worth $12.7M as of Q3 2024.
  • Eagle Asset Management sold 12,657 Krystal Biotech shares in Q3 2024, an estimated $2.44M.
  • Krystal Biotech made up 0.06% of Eagle Asset Management's portfolio in Q3 2024, its #250 holding.
  • Eagle Asset Management first reported a position in Krystal Biotech in Q2 2024 and has held it in 2 quarters since.
  • Eagle Asset Management's Krystal Biotech position peaked at $13.9M in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.